AU2021391823A1 - Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery - Google Patents

Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery Download PDF

Info

Publication number
AU2021391823A1
AU2021391823A1 AU2021391823A AU2021391823A AU2021391823A1 AU 2021391823 A1 AU2021391823 A1 AU 2021391823A1 AU 2021391823 A AU2021391823 A AU 2021391823A AU 2021391823 A AU2021391823 A AU 2021391823A AU 2021391823 A1 AU2021391823 A1 AU 2021391823A1
Authority
AU
Australia
Prior art keywords
block copolymer
composition
methacrylate
dna
raft block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021391823A
Other languages
English (en)
Other versions
AU2021391823A9 (en
Inventor
Anthony D. DUONG
Cherry GUPTA
Danielle HUK
Mike KOERIS
Stephanie M. KUTE
Jacob LILLY
Kenneth R. SIMS JR.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Battelle Memorial Institute Inc
Original Assignee
Battelle Memorial Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute Inc filed Critical Battelle Memorial Institute Inc
Publication of AU2021391823A1 publication Critical patent/AU2021391823A1/en
Publication of AU2021391823A9 publication Critical patent/AU2021391823A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y35/00—Methods or apparatus for measurement or analysis of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Analytical Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Medical Informatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021391823A 2020-12-03 2021-12-03 Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery Pending AU2021391823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121202P 2020-12-03 2020-12-03
US63/121,202 2020-12-03
PCT/US2021/061846 WO2022120194A1 (en) 2020-12-03 2021-12-03 Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery

Publications (2)

Publication Number Publication Date
AU2021391823A1 true AU2021391823A1 (en) 2023-06-29
AU2021391823A9 AU2021391823A9 (en) 2024-10-10

Family

ID=81849538

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021391823A Pending AU2021391823A1 (en) 2020-12-03 2021-12-03 Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery

Country Status (8)

Country Link
US (4) US20220175812A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255495A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553010A (cg-RX-API-DMAC7.html)
CN (1) CN116887866A (cg-RX-API-DMAC7.html)
AU (1) AU2021391823A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203975A1 (cg-RX-API-DMAC7.html)
IL (1) IL303390A (cg-RX-API-DMAC7.html)
WO (1) WO2022120194A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN116343955B (zh) * 2022-12-29 2026-03-24 中国工商银行股份有限公司 基于纳米材料的参数预测方法和装置、处理器及电子设备
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
EP4784651A1 (en) * 2023-09-29 2026-08-05 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery to the central nervous system
AU2024349841A1 (en) * 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
WO2025250979A1 (en) 2024-05-31 2025-12-04 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
WO2026035659A1 (en) * 2024-08-05 2026-02-12 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
US20260090998A1 (en) * 2024-10-02 2026-04-02 Battelle Memorial Institute Methods of using polymer nanoparticle compositions for treating a disease
CN119666949B (zh) * 2024-11-28 2026-02-27 昆明理工大学 一种电化学适配体传感器及其制备方法和应用

Family Cites Families (578)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1198052A (en) 1965-02-12 1970-07-08 Ici Ltd Polymer Dispersions
SE339105B (cg-RX-API-DMAC7.html) 1966-02-23 1971-09-27 Avisun Corp
US3847857A (en) 1967-11-02 1974-11-12 Rohm & Haas Stain resistant coating composition
US3562806A (en) 1968-09-10 1971-02-09 Eastman Kodak Co Rumen stable medicament and/or nutrient compositions
US3678098A (en) 1969-04-04 1972-07-18 Rohm & Haas Unsaturated quaternary monomers and polymers
GB1324087A (en) 1969-07-18 1973-07-18 Commw Scient Ind Res Org Copolymers and veterinary compositions treated therewith
GB1284489A (en) 1970-03-16 1972-08-09 Ici Ltd Thermoplastic polymer blends
US3744969A (en) 1970-06-09 1973-07-10 Rohm & Haas Break resistant leather
US3829564A (en) 1970-07-17 1974-08-13 Commw Scient Ind Res Org Coated products for veterinary use
US3706565A (en) 1970-10-28 1972-12-19 Eastman Kodak Co Photographic compositions containing an admixture of organic and inorganic silver salts
US3706564A (en) 1970-10-28 1972-12-19 Eastman Kodak Co Process for forming silver halide crystals in the presence of amphiphilic copolymers
GB1314285A (en) 1970-12-16 1973-04-18 Ici Australia Ltd Explosive compositions
US4056559A (en) 1971-04-23 1977-11-01 Rohm And Haas Company Novel polymers of alkyl methacrylates
IL45712A (en) 1973-10-02 1977-10-31 Hydrophilics Int Inc Hydrophilic copolymer salt and its use
JPS5156886A (ja) 1974-11-14 1976-05-18 Unitika Ltd Horiionkonpuretsukusuno seizoho
JPS5320051B2 (cg-RX-API-DMAC7.html) 1975-02-28 1978-06-24
US4036766A (en) 1976-06-14 1977-07-19 Texaco Inc. Polymethacrylate additives and lube compositions thereof
US4237253A (en) 1977-04-21 1980-12-02 L'oreal Copolymers, their process of preparation, and cosmetic compounds containing them
DE2861140D1 (en) 1977-11-29 1981-12-17 Bexford Ltd Vesicular recording materials
KR830001200B1 (ko) 1979-02-05 1983-06-21 이와마 가즈오 자기 헤드의 트랙킹 장치
US4377481A (en) 1980-11-14 1983-03-22 Abcor, Inc. Blended, polymeric, matrix membrane and process of making and using same
DE3271303D1 (en) 1981-03-19 1986-07-03 Ici Plc Process for producing stable dispersions in water-dilutable liquid media of halogen-containing addition polymer, employing a polymeric dispersant, and waterborne coating compositions based on dispersions so made
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
JPS57211146A (en) 1981-06-23 1982-12-24 Fuji Photo Film Co Ltd Photopolymerizable composition
US4544621A (en) 1982-05-19 1985-10-01 Ciba Geigy Corporation Photocrosslinkable water-soluble polymers, containing maleimidyl and quaternary ammonium groups process for their preparation and use thereof
US4559293A (en) 1983-04-08 1985-12-17 Kimoto & Co., Ltd. Photosensitive recording material developable with aqueous neutral salt solution
NZ209347A (en) 1983-09-09 1987-06-30 Dulux Australia Ltd Thermoplastic coating composition containing at least one acrylic polymer and at least two plasticisers
US4592816A (en) 1984-09-26 1986-06-03 Rohm And Haas Company Electrophoretic deposition process
EP0199306B1 (en) 1985-04-22 1992-03-11 E.I. Du Pont De Nemours And Company Wash-off film containing synthetic amphoteric polymers
EP0217137B1 (en) 1985-08-29 1992-04-08 E.I. Du Pont De Nemours And Company Photopolymerizable composition of acrylic copolymer containing dicyclopentenyl acrylate or methacrylate
EP0243177B1 (en) 1986-04-23 1993-07-07 Sumitomo Chemical Company, Limited Catalytic production of polyamide block copolymers
US5969046A (en) 1986-11-18 1999-10-19 Rohm And Haas Company Reacting methylene and alkene components in presence of tertiary amine reacted with epoxide
US4755563A (en) 1986-12-29 1988-07-05 E. I. Du Pont De Nemours And Company Block copolymer dispersants containing ionic moieties
JP2697818B2 (ja) 1987-03-13 1998-01-14 株式会社リコー 加熱定着用現像剤
US4834799A (en) 1987-10-27 1989-05-30 Videojet Systems International, Inc. Jet ink for vinyl substrate marking
JP2680594B2 (ja) 1988-03-02 1997-11-19 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー ブロツク共重合体分散剤
US4925764A (en) 1988-12-23 1990-05-15 E. I. Du Pont De Nemours & Co. Positive solid block toner
US4985160A (en) 1989-02-08 1991-01-15 E. I. Du Pont De Nemours And Company Branched polymers as fuel oil additives
EP0473757A1 (en) 1990-02-28 1992-03-11 DowBrands Inc. Ionizable polymer cleaning compositions and methods for cleaning stains
US5085698A (en) 1990-04-11 1992-02-04 E. I. Du Pont De Nemours And Company Aqueous pigmented inks for ink jet printers
US5124381A (en) 1990-11-08 1992-06-23 Armstrong World Industries, Inc. Acrylic polymer coating compositions for coats and films that have reduced surface resistivity
DE4110027C2 (de) 1991-03-27 1996-08-29 Lohmann Therapie Syst Lts Verfahren zur Konfektionierung transdermaler therapeutischer Pflaster
US5141556A (en) 1991-06-13 1992-08-25 E. I. Du Pont De Nemours And Company Penetrants for aqueous ink jet inks
US5205861A (en) 1991-10-09 1993-04-27 E. I. Du Pont De Nemours And Company Aqueous ink jet inks containing alkylene oxide condensates of certain nitrogen heterocyclic compounds as cosolvents
US5180425A (en) 1991-11-05 1993-01-19 E. I. Du Pont De Nemours And Company Aqueous ink jet inks containing polyol/alkylene oxide condensates as cosolvents
US5519081A (en) 1991-11-15 1996-05-21 Imperial Chemical Industries Plc Polymerisable compositions
US5271765A (en) 1992-02-03 1993-12-21 E. I. Du Pont De Nemours And Company Aqueous cationic dye-based ink jet inks
DE69325401T2 (de) 1992-02-20 1999-11-25 E.I. Du Pont De Nemours & Co., Inc. Dreiblock-Polymer Dispersionsmittel enthaltende Wasserdispersionen
US5428383A (en) 1992-08-05 1995-06-27 Hewlett-Packard Corporation Method and apparatus for preventing color bleed in a multi-ink printing system
US5310778A (en) 1992-08-25 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing ink jet inks having improved properties
CA2104976A1 (en) 1992-09-02 1994-03-03 Stephan D. Daubney Separation of plasma or serum from whole blood using a red blood cell binding component and a polymer containing multiple cationic sites
JPH06145262A (ja) 1992-09-03 1994-05-24 Rohm & Haas Co 多段階ポリマーを含有する耐水性組成物
US5310595A (en) 1992-09-18 1994-05-10 Minnesota Mining And Manufacturing Company Water-based transparent image recording sheet for plain paper copiers
US5432035A (en) 1992-12-18 1995-07-11 Fujitsu Limited Flash fixing color toner and process for producing the same
US5512418A (en) 1993-03-10 1996-04-30 E. I. Du Pont De Nemours And Company Infra-red sensitive aqueous wash-off photoimaging element
US5620883A (en) 1994-04-01 1997-04-15 The Johns Hopkins University Living cells microencapsulated in a polymeric membrane having two layers
US5418277A (en) 1994-04-26 1995-05-23 E. I. Du Pont De Nemours And Company Aqueous ink jet inks containing fluorinated polymers
EP0753551B1 (en) 1995-07-11 2000-02-09 E.I. Du Pont De Nemours And Company Ink set and process for alleviating bleed in printed elements
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
TW438608B (en) 1995-08-02 2001-06-07 Hisamitsu Pharmaceutical Co A tablet containing anion exchange resin
US5518534A (en) 1995-08-04 1996-05-21 E. I. Du Pont De Nemours And Company Ink set and process for alleviating bleed in printed elements
US5525450A (en) 1995-09-01 1996-06-11 Xerox Corporation Liquid developer compositions with multiple block copolymers
DE69634697T2 (de) 1995-10-25 2006-05-04 Octoplus B.V. Kationische polyacrylate und poly(alkyl)acrylate oder die entsprechende acrylamide zur verwendung in synthetischen transfektions-systemen
US7256020B2 (en) 1996-11-29 2007-08-14 Third Wave Technologies, Inc. Methods and compositions for detecting target sequences
US5709714A (en) 1996-03-11 1998-01-20 Rohm And Haas Company Method of treating leather with amphoteric polymers
US5698016A (en) 1996-06-14 1997-12-16 Cabot Corporation Compositions of modified carbon products and amphiphilic ions and methods of using the same
JP4010585B2 (ja) 1996-10-15 2007-11-21 久光製薬株式会社 陰イオン交換樹脂を含有する錠剤
US6040358A (en) 1996-12-27 2000-03-21 E. I. Du Pont De Nemours And Company Ink jet inks containing linear polymer additives
WO1998051749A1 (en) 1997-05-12 1998-11-19 The General Electric Company, Plc Sedimentation free jet ink composition
US6004582A (en) 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
EP0886187B1 (en) 1997-06-18 2003-10-15 Canon Kabushiki Kaisha Toner, two-component developer and image forming method
US6221402B1 (en) 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
KR100404534B1 (ko) 1997-11-21 2003-11-05 더 프록터 앤드 갬블 캄파니 중합체성 거품 증진제를 포함하는 세제 조성물 및 이를 사용한 거품 용적과 거품 보유율의 증진방법
JP2001524587A (ja) 1997-11-21 2001-12-04 ザ、プロクター、エンド、ギャンブル、カンパニー 高分子泡改善剤を含んでなる液体洗剤組成物
US6139856A (en) 1997-12-11 2000-10-31 Biomedical Development Corp. Composition useful for providing one-step surgical preparation and drape
US6720387B1 (en) 1998-02-18 2004-04-13 3M Innovative Properties Company Hot-melt adhesive compositions comprising acidic polymer and basic polymer blends
EP0945148B1 (en) 1998-03-26 2003-11-26 Biomat B.V. Endovascular stents with a polymeric coating
US6247808B1 (en) 1998-04-22 2001-06-19 Hewlett-Packard Company Ink-jet printing system for improved print quality
US6022908A (en) 1998-04-22 2000-02-08 Hewlett-Packard Company Printing liquids for improved print quality
JPH11335269A (ja) 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
DE19918435A1 (de) 1998-07-23 2000-01-27 Roehm Gmbh Überzugs- und Bindemittel für orale oder dermale Arzneiformen
US6004712A (en) 1998-08-26 1999-12-21 Xerox Corporation Coated carrier
CA2347104A1 (en) 1998-10-26 2000-04-05 Tanabe Seiyaku Co., Ltd. Sustained-release particles
DE69912078T2 (de) 1998-12-10 2004-08-26 E.I. Du Pont De Nemours And Co., Wilmington Tintenstrahldrucktinten, die sternförmige Polymerzusätze enthalten
US6245421B1 (en) 1999-02-04 2001-06-12 Kodak Polychrome Graphics Llc Printable media for lithographic printing having a porous, hydrophilic layer and a method for the production thereof
US6903064B1 (en) 1999-05-26 2005-06-07 Procter & Gamble Company Detergent composition comprising polymeric suds volume and suds duration enhancers
US7241729B2 (en) 1999-05-26 2007-07-10 Rhodia Inc. Compositions and methods for using polymeric suds enhancers
US6827795B1 (en) 1999-05-26 2004-12-07 Procter & Gamble Company Detergent composition comprising polymeric suds enhancers which have improved mildness and skin feel
US6276273B1 (en) 1999-06-11 2001-08-21 Kodak Polychrome Graphics Llc Surfactant-pretreated printing plate substrate, lithographic printing plate and method for production thereof
US6413306B1 (en) 1999-10-07 2002-07-02 E. I. Du Pont De Nemours And Company Pigment dispersions containing ABC-block polymer dispersant
AU2764801A (en) 2000-01-07 2001-07-24 University Of Washington Enhanced transport of agents using membrane disruptive agents
US6532871B1 (en) 2000-01-27 2003-03-18 Kodak Polychrome Graphics Llc Method of controlling image resolution on a substrate using an autophobic fluid
US6471349B1 (en) 2000-01-27 2002-10-29 Kodak Polychrome Graphics Llc Method to prepare a printing plate and printing plate
US6132917A (en) 2000-03-29 2000-10-17 Xerox Corporation Coated carrier
US6251554B1 (en) 2000-03-29 2001-06-26 Xerox Corporation Coated carrier
US6653056B2 (en) 2000-07-12 2003-11-25 E. I. Du Pont Nemours And Company Process for patterning non-photoimagable ceramic tape
KR20020016069A (ko) 2000-08-24 2002-03-04 민경윤 마크로라이드계 항생제의 경구투여용 조성물 및 이의 제조방법
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
HK1054195B (zh) 2001-02-27 2005-09-09 Evonik Röhm Gmbh 用於提高了儲存穩定性的藥物製劑的包衣及粘合劑
DE10110391A1 (de) 2001-03-03 2002-09-26 Lohmann Therapie Syst Lts Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff
US20040109869A1 (en) 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
JP2004525803A (ja) 2001-04-12 2004-08-26 エーブリー デニソン コーポレイション 金属被覆インクジェット基材およびそれを作製する方法
DE10127134A1 (de) 2001-06-05 2002-12-12 Roehm Gmbh verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß
CN1152067C (zh) 2001-06-20 2004-06-02 山东大学 药物包衣用水性高分子薄膜材料制备工艺
EP1416922A1 (en) 2001-07-16 2004-05-12 AstraZeneca AB Pharmaceutical formulation comprising a proton pump inhibitor and antacids
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
CN1168797C (zh) 2001-07-23 2004-09-29 广西南宁博世科工贸有限责任公司 纳米级纸质餐饮具防水剂及其生产方法
US7055943B2 (en) 2001-08-22 2006-06-06 Canon Kabushiki Kaisha Ink set for ink-jet recording, recording unit, ink-jet recording apparatus and ink-jet recording method
DE60204932T2 (de) 2001-09-28 2006-05-18 Canon K.K. Toner und Bildaufzeichnungsmethode
US7048771B2 (en) 2001-10-22 2006-05-23 University Of California Dyeing textiles using nanoparticles
CO5390081A1 (es) 2001-11-28 2004-04-30 Novartis Ag Compuestos organicos
FR2832719B1 (fr) 2001-11-29 2004-02-13 Oreal Copolymeres ethyleniques sequences adhesifs, compositions cosmetiques les contenant, et utilisation de ces copolymeres en cosmetique
FR2832720B1 (fr) 2001-11-29 2004-02-13 Oreal Copolymeres ethyleniques sequences, compositions cosmetiques les contenant, et utilisation de ces copolymeres en cosmetique
DE10160720A1 (de) 2001-12-11 2003-06-18 Basf Ag Kosmetisches Mittel enthaltend wenigstens ein Copolymer mit N-Vinyllactameinheiten
GB0130499D0 (en) 2001-12-20 2002-02-06 Unilever Plc Polymers for laundry cleaning compositions
KR100619380B1 (ko) 2002-03-28 2006-09-05 한미약품 주식회사 마크로라이드계 항생제의 경구투여용 조성물 및 이의제제화 방법
KR20050023239A (ko) 2002-03-29 2005-03-09 알자 코포레이션 용적 효율적인 조절된 방출 투여 형태
US6924259B2 (en) 2002-04-17 2005-08-02 National Starch And Chemical Investment Holding Corporation Amine copolymers for textile and fabric protection
WO2003090780A1 (en) 2002-04-26 2003-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Direct cell target analysis
JP2003345095A (ja) 2002-05-30 2003-12-03 Canon Inc 電子写真用部材の製造方法及び該方法により製造された電子写真用部材
DE10239999A1 (de) 2002-08-27 2004-03-04 Röhm GmbH & Co. KG Granulat oder Pulver zur Herstellung von Überzugs- und Bindemitteln für Arzneiformen
JP4213432B2 (ja) 2002-08-28 2009-01-21 久光製薬株式会社 貼付剤
WO2004041255A1 (en) 2002-10-31 2004-05-21 Alza Corporation Dosage form providing ascending release of liquid formulation
DE10260921A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
AU2004228083B2 (en) 2003-04-07 2009-03-26 Rimon Therapeutics Ltd. Ancient defense polymer
TR200300510A2 (tr) 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
WO2004096422A1 (en) 2003-04-30 2004-11-11 The University Of Sheffield Particulate emulsifiers, emulsions and uses thereof
US20050090599A1 (en) 2003-06-06 2005-04-28 Spinelli Harry J. Aqueous ionically stabilized dispersions
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
GB2407501A (en) 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
GB2407500A (en) 2003-11-03 2005-05-04 Ist Superiore Sanita Use of microparticles for antigen delivery
US7829070B2 (en) 2003-12-09 2010-11-09 Basf Se Ampholytic anionic copolymers
CN1909889B (zh) 2004-01-09 2010-06-02 韩美药品株式会社 头孢呋辛酯颗粒及其制备方法
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP4696107B2 (ja) 2004-03-24 2011-06-08 コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ ブクホルジア属に属する植物の抽出物の化粧品および医薬品における使用
US8652456B2 (en) 2004-06-21 2014-02-18 Basf Se Aqueous preparations comprising at least one water-soluble or water-dispersible copolymer with cationgenic groups
DE102004035938A1 (de) 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil
DE102004051541A1 (de) 2004-10-22 2006-05-04 Basf Ag Amphotere Ethylmethacrylat-Copolymere und deren Verwendung
DE102004051648A1 (de) 2004-10-22 2006-04-27 Basf Ag Anionische Ethylmethacrylat-Copolymere und deren Verwendung
US7499209B2 (en) 2004-10-26 2009-03-03 Xerox Corporation Toner compositions for dry-powder electrophoretic displays
DE102004059792A1 (de) 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
WO2006079632A1 (de) 2005-01-28 2006-08-03 Basf Aktiengesellschaft Verwendung von wasser-in-wasser-emulsionspolymerisaten als verdicker in kosmetischen zubereitungen
DE102005010255A1 (de) 2005-03-07 2006-09-14 Lts Lohmann Therapie-Systeme Ag Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
US8445382B2 (en) 2005-03-22 2013-05-21 Nxp B.V. Side wall pore sealing for low-k dielectrics
CN101232868A (zh) 2005-04-19 2008-07-30 阿尔扎公司 曲马多和加巴喷丁的控释递药剂型
WO2006122022A2 (en) 2005-05-10 2006-11-16 Novartis Ag Modified release famciclovir pharmaceutical compositions
NZ585116A (en) 2005-05-10 2011-12-22 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US7842793B2 (en) * 2005-06-14 2010-11-30 The California Institute Of Technology Methods of making nucleic acid nanostructures
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
RU2423997C9 (ru) 2005-07-05 2011-11-20 Эббетт ГмбХ унд Ко. КГ Композиция и лекарственная форма, содержащие твердую или полутвердую матрицу
US20070275060A1 (en) 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
WO2007020187A1 (en) 2005-08-12 2007-02-22 Ciba Specialty Chemicals Holding Inc. Strongly adherent coatings
GB0518059D0 (en) 2005-09-06 2005-10-12 Dow Corning Delivery system for releasing active ingredients
US7642329B2 (en) 2005-09-27 2010-01-05 Council Of Scientific & Industrial Research Oligomeric lactide macromer based copolymer and a process for the preparation thereof
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
AU2006340003A1 (en) 2005-11-09 2007-09-20 Novartis Ag Process for making pharmaceutical compositions with a transient plasticizer
WO2007060117A2 (de) 2005-11-24 2007-05-31 Basf Se Chimäre keratinbindende effektorproteine
GB2432584A (en) 2005-11-28 2007-05-30 Univ Sheffield Particle stabilised foam
CN1813683B (zh) 2005-12-07 2011-08-31 范敏华 一种阿奇霉素的干混悬剂及其制备方法
US7579504B2 (en) 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US20110163469A1 (en) 2005-12-16 2011-07-07 Massachusetts Institute Of Technology High-throughput fabrication of microparticles
GB0525864D0 (en) 2005-12-20 2006-02-01 Novartis Ag Organic compounds
CN100450597C (zh) 2005-12-27 2009-01-14 天津工业大学 一种复合纳滤膜及其制备方法
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
US20100233350A1 (en) 2006-03-15 2010-09-16 Boston Scientific Scimed, Inc. Drug delivery composition and methods of making same using nanofabrication
KR20090005347A (ko) 2006-03-31 2009-01-13 바스프 에스이 아크릴레이트 공중합체의 제조 방법
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CA2649848A1 (en) 2006-05-04 2007-11-15 Novartis Ag Heated roller compaction process for making pharmaceutical compositions
CN101460156B (zh) 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
CN100500716C (zh) 2006-06-21 2009-06-17 苏州大学 无规共聚阳离子大分子乳化剂及其制备方法
AU2007265452A1 (en) 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
KR100857724B1 (ko) 2006-06-30 2008-09-10 한올제약주식회사 용해도와 용출률이 향상된 시부트라민 함유 경구투여용 고체분산체
CN101484144A (zh) 2006-07-06 2009-07-15 特瓦特药工业有限公司 具有受控药物动力学的组合物
SI1880718T1 (sl) 2006-07-10 2011-11-30 Pfleger R Chem Fab Farmacevtski pripravki za oralno dajanje z nadzorovanim sproščanjem zdravila v majhne intestinke kolone in postopek njihove priprave
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
KR100857411B1 (ko) 2006-07-21 2008-09-08 한올제약주식회사 리파아제 저해제의 경구 투여용 방출조절 약학 제제 및이의 제조 방법
ATE462416T1 (de) 2006-08-04 2010-04-15 Ethypharm Sa Mehrschichtige im mund zerfallende tablette
WO2008021347A2 (en) 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
WO2008023869A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
CA2662911A1 (en) 2006-09-19 2008-03-27 Basf Se Cosmetic preparations based on molecularly imprinted polymers
KR100812538B1 (ko) 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
WO2008054123A1 (en) 2006-10-30 2008-05-08 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
WO2008054121A1 (en) 2006-10-30 2008-05-08 Hanall Pharmaceutical Company. Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
WO2008055966A1 (en) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
GB0624729D0 (en) 2006-12-12 2007-01-17 Univ Leeds Reversible micelles and applications for their use
US20080153982A1 (en) 2006-12-20 2008-06-26 John Ta-Yuan Lai Vinyl-Thiocarbonate and Polyol Containing Block Copolymers
WO2008093984A1 (en) 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US8298452B2 (en) 2007-02-26 2012-10-30 Dai Nippon Printing Co., Ltd. Negative type resist composition for color filter, color filter using same, and liquid crystal display
WO2008117814A1 (ja) 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
JP5215642B2 (ja) 2007-03-30 2013-06-19 富士フイルム株式会社 インク組成物、並びに、それを用いた画像記録方法及び画像記録物
JP5260943B2 (ja) 2007-03-30 2013-08-14 富士フイルム株式会社 粒子分散物及びインク組成物、並びに、それを用いた画像記録方法及び画像記録物
JP5215641B2 (ja) 2007-03-30 2013-06-19 富士フイルム株式会社 インク組成物、並びに、それを用いた画像記録方法及び画像記録物
KR101128891B1 (ko) 2007-05-03 2012-03-26 한올바이오파마주식회사 로라타딘 및 슈도에페드린을 함유하는 제어 방출 다층정
US20080299391A1 (en) 2007-05-31 2008-12-04 White Scott R Capsules, methods for making capsules, and self-healing composites including the same
CN101796186B (zh) 2007-06-07 2013-05-22 韦克福里斯特大学健康科学院 喷墨基因打印
KR100867639B1 (ko) 2007-06-08 2008-11-10 (주)다산메디켐 고미가 차폐된 염산 도네페질-함유 입자, 이를 포함하는약학 조성물, 및 이들의 제조방법
WO2008157611A2 (en) 2007-06-18 2008-12-24 3M Innovative Properties Company Colored acrylic adhesive and marking film
JP2009016258A (ja) 2007-07-06 2009-01-22 Mitsubishi Electric Corp 固体高分子型燃料電池
JP5581208B2 (ja) 2007-07-18 2014-08-27 データレース リミテッド レーザー感受性被覆配合物
WO2009026461A2 (en) 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
KR101050015B1 (ko) 2007-09-21 2011-07-19 동아제약주식회사 위체류약물전달시스템을 이용한 애엽 추출물의 약학조성물및 이를 이용한 서방성 경구용 제제
AR066168A1 (es) 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
FR2921835B1 (fr) 2007-10-05 2012-05-04 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables
CN101932322A (zh) 2007-10-10 2010-12-29 韩诺生物制约株式会社 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物
CN101444513B (zh) 2007-11-27 2011-05-11 上官清 一种头孢克洛口腔崩解片及其制备方法
US20100278899A1 (en) 2007-12-06 2010-11-04 Lintec Corporation Edible film
US7932306B2 (en) 2007-12-12 2011-04-26 E. I. Du Pont De Nemours And Company Amphoteric dispersants and their use in inkjet inks
DE102007060175A1 (de) 2007-12-13 2009-06-18 Johannes Gutenberg-Universität Mainz Quartärnisierung des Zusatzstoffs Aminoalkyl Methacrylat Copolymer E zur Verbesserung der Permeabilität und Löslichkeit von Arzneistoffen
US8034254B2 (en) 2007-12-21 2011-10-11 3M Innovative Properties Company Optical adhesive for liquid crystal display
EP2224901A1 (en) 2007-12-21 2010-09-08 Basf Se Anti-dandruff compositions containing peptides
KR101288294B1 (ko) 2007-12-25 2013-07-26 닛뽕소다 가부시키가이샤 오늄염 함유 폴리머
KR101104912B1 (ko) 2008-01-08 2012-01-12 한올바이오파마주식회사 N,n―디메틸 이미도디카르본이미딕 디아미드의 니코틴산염, 그의 제조방법 및 그를 포함하는 약제학적 조성물
EP2246052B1 (en) 2008-01-31 2017-03-08 Kyorin Pharmaceutical Co., Ltd. Orally rapidly disintegrating tablet comprising imidafenacin
CN101983055B (zh) 2008-01-31 2013-05-08 杏林制药株式会社 以咪达那新为有效成分的口腔内速崩片的制造方法
AU2009214307A1 (en) 2008-02-13 2009-08-20 Bayer Intellectual Property Gmbh Drug delivery system with stabilising effect
WO2009103735A1 (de) 2008-02-21 2009-08-27 Basf Se Zusammensetzung, enthaltend ein ampholytisches copolymer auf der basis quaternisierter stickstoffhaltiger monomere und mindestens ein hiervon verschiedenes polymer, und ihre verwendung
KR20090091075A (ko) 2008-02-22 2009-08-26 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
WO2009104939A2 (ko) 2008-02-22 2009-08-27 한올제약주식회사 약제학적 제제
KR101207618B1 (ko) 2008-02-22 2012-12-04 한올바이오파마주식회사 심혈관계 질환 치료용 약제학적 제제
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
WO2009125981A2 (ko) 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2009125987A2 (ko) 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
KR20090114190A (ko) 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 HMG―CoA 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
KR101209319B1 (ko) 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
WO2009134053A2 (ko) 2008-04-29 2009-11-05 한올제약주식회사 방출성이 제어된 차이자이드계 화합물과 안지오텐신 - ii - 수용체 차단제를 포함하는 약학적 조성물
KR101230731B1 (ko) 2008-04-29 2013-02-07 한올바이오파마주식회사 약제학적 제제
CA2724014C (en) 2008-05-13 2016-09-13 University Of Washington Micellic assemblies
WO2009140421A2 (en) * 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
WO2009142421A2 (ko) 2008-05-17 2009-11-26 한올제약주식회사 약제학적 제제
JP2011521085A (ja) 2008-05-22 2011-07-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー インクジェットインクと共に用いられる定着インク
GB0809314D0 (en) 2008-05-22 2008-07-02 Summit Corp Plc Compounds for treating muscular dystrophy
WO2009151295A2 (ko) 2008-06-13 2009-12-17 한올제약주식회사 아젤니디핀과 HMG-CoA 환원효소 억제제 또는 안지오텐신 Ⅱ 수용체 차단제를 포함하는 약제학적 제제
US8366600B2 (en) 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
US8664324B2 (en) 2008-06-23 2014-03-04 Basf Se Pigment dispersants with modified copolymers
WO2010008203A2 (ko) 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
WO2010008244A2 (ko) 2008-07-18 2010-01-21 한올제약주식회사 약제학적 제제
JP5881292B2 (ja) 2008-09-08 2016-03-09 国立大学法人京都大学 リビングラジカル重合法のための触媒
CA2776672A1 (en) 2008-10-03 2010-04-08 Chamelic Ltd Ab diblock copolymers and applications for their use
US9267042B2 (en) 2008-10-27 2016-02-23 Datalase Ltd. Coating composition for marking substrates
BRPI0921231A2 (pt) 2008-11-05 2018-06-26 Lubrizol Corp composição contendo um copolímero em bloco e um método para lubrificação de um motor de combustão interna
JP2010111781A (ja) 2008-11-06 2010-05-20 Kao Corp 非水系顔料分散剤
DE102008043662A1 (de) 2008-11-12 2010-05-20 Evonik Röhm Gmbh Verfahren zur Herstellung von Telechelen mit breiter Molekulargewichtsverteilung
CA2745926A1 (en) 2008-12-08 2010-07-08 Phaserx, Inc. Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization
US8820907B2 (en) 2008-12-12 2014-09-02 E I Du Pont De Nemours And Company Amphoteric dispersants and their use in inkjet inks
TWI468191B (zh) 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
CN101643412B (zh) 2009-03-17 2013-03-13 江苏工业学院 一种端羟基聚丙烯酸酯类齐聚物及制备方法与用途
JP5654002B2 (ja) 2009-05-13 2015-01-14 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se ポリエーテルに基づくコポリマーを微水溶性ポリマーと組み合わせて含む固体医薬調製物
US7992656B2 (en) 2009-07-09 2011-08-09 Halliburton Energy Services, Inc. Self healing filter-cake removal system for open hole completions
KR101326900B1 (ko) 2009-08-21 2013-11-11 이화여자대학교 산학협력단 신규한 항암제 보조용 화합물, 이의 제조방법 및 이를 포함하는 항암제 보조용 조성물
KR101190953B1 (ko) 2009-08-25 2012-10-12 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025271A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101190957B1 (ko) 2009-08-25 2012-10-15 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025267A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
EP2289971A1 (en) 2009-08-27 2011-03-02 Total Petrochemicals Research Feluy Ring opening polymerisation of cyclic carbonates with organic catalyst systems
KR101630432B1 (ko) 2009-08-28 2016-06-15 한국생명공학연구원 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
KR101280160B1 (ko) 2009-09-02 2013-06-28 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
JP5868319B2 (ja) 2009-09-03 2016-02-24 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングEvonik Roehm GmbH 1つ以上の生物学的活性物質、調合補助物質および磁化可能粒子を包含する経口剤形
CN102030871B (zh) 2009-09-25 2012-10-10 天津大学 聚乙二醇嵌段可生物降解聚酯梳型接枝共聚物及其制备方法和应用
CN102482546B (zh) 2009-09-29 2015-11-25 琳得科株式会社 粘合剂以及粘合片
JP5583379B2 (ja) 2009-09-30 2014-09-03 富士フイルム株式会社 顔料分散物及びそれを用いたインク組成物
KR101110845B1 (ko) 2009-10-21 2012-02-15 주식회사 케이씨씨 내수성 및 내후성이 우수한 방담 코팅용 조성물
CN102665671B (zh) 2009-10-22 2015-06-10 欧莱雅 光照保护性组合物与薄膜及其制造方法
WO2011062965A2 (en) 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
WO2011074637A1 (ja) 2009-12-16 2011-06-23 後藤 武 抗認知症薬物の経皮吸収製剤
JP2012236773A (ja) 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
US20120282303A1 (en) 2009-12-16 2012-11-08 Takeshi Ito Percutaneous absorption preparation comprising anti-dementia drug
EA201200935A1 (ru) 2009-12-23 2012-12-28 Дефианте Фармасеутика С.А. Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний
CN101735383B (zh) 2009-12-25 2014-08-13 天津大学 聚甲基丙烯酸二甲胺基乙酯-聚甲基丙烯酸盐包裹氧化锌量子点及制备和应用
EP2525780B1 (en) 2010-01-19 2022-09-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
JP2011184582A (ja) 2010-03-09 2011-09-22 Three M Innovative Properties Co 光学用粘着シート
GB201003970D0 (en) 2010-03-10 2010-04-21 Univ Sheffield Polymer synthesis
US20110312973A1 (en) 2010-03-10 2011-12-22 Bernd Liepold Solid compositions
US20130005874A1 (en) 2010-03-15 2013-01-03 Taisho Pharmaceutical Co., Ltd Pigment composition
JP4620171B1 (ja) 2010-03-19 2011-01-26 株式会社ツキオカ 可食フィルム
US20130017245A1 (en) 2010-03-23 2013-01-17 Aska Pharmaceutical Co., Ltd. Solid preparation
JP2011207963A (ja) 2010-03-29 2011-10-20 Fujifilm Corp 顔料分散物、インク組成物、インクジェット記録方法、および印刷物
JP2013527155A (ja) 2010-04-16 2013-06-27 ダボス ライフ サイエンス ピーティーイー. リミテッド 皮膚科用途のための少なくとも1つのビタミンe成分およびチロシナーゼ阻害剤の相乗的相互作用
KR20110117758A (ko) 2010-04-22 2011-10-28 한올바이오파마주식회사 베타 아드레날린 차단제 및 HMG-CoA 환원 효소 억제제를 함유하는 약제학적 제제
KR101324283B1 (ko) 2010-04-27 2013-11-01 한올바이오파마주식회사 바이구아나이드 화합물의 신규 염, 그의 제조방법, 그를 포함하는 약제학적 조성물
GB201008364D0 (en) 2010-05-20 2010-07-07 Geneve De Composition and method
CN101890185B (zh) 2010-05-21 2012-12-12 天津大学 含有ZnO量子点载体/DNA复合物的胶原基复合角膜替代物及其制备方法和应用
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
KR20110135018A (ko) 2010-06-10 2011-12-16 연세대학교 산학협력단 암의 치료 또는 예방을 위한 약제학적 조성물
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
KR101372721B1 (ko) 2010-06-18 2014-03-14 이화여자대학교 산학협력단 Interleukin―6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
NZ605352A (en) 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
KR101463677B1 (ko) 2010-06-30 2014-11-19 닛뽕소다 가부시키가이샤 신규 공중합체
KR100994148B1 (ko) 2010-07-14 2010-11-15 (주)아팩 그라비아 인쇄용 양이온성 수성 수지 조성물 및 그의 제조방법
US9121065B2 (en) 2010-08-09 2015-09-01 The Trustees Of The University Of Pennsylvania Nanoparticle-oligonucleotide hybrid structures and methods of use thereof
KR101659785B1 (ko) 2010-10-22 2016-09-26 한국생명공학연구원 Il-6 활성 억제 작용을 갖는 화합물 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 il-6로 매개되는 질환의 예방 또는 치료용 조성물
EP3974831A1 (en) 2010-10-22 2022-03-30 T2 Biosystems, Inc. Methods for detecting the presence of a bacterium in a whole blood sample
WO2012058638A2 (en) 2010-10-29 2012-05-03 President And Fellows Of Harvard College Nucleic acid nanostructure barcode probes
WO2012061719A2 (en) 2010-11-04 2012-05-10 President And Fellows Of Harvard College Dna origami devices
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
MX354210B (es) 2010-12-16 2018-02-16 Celgene Corp Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
IE20100799A1 (en) 2010-12-22 2012-08-01 Eurand Pharmaceuticals Ltd Pharmaceutical composites of poorly water soluble drugs and polymers
WO2012101235A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
KR101730865B1 (ko) 2011-02-11 2017-04-27 주식회사유한양행 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
KR20120098489A (ko) 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물
KR20120098462A (ko) 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
CN103415284B (zh) 2011-03-09 2016-12-07 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制物
KR101314579B1 (ko) 2011-04-07 2013-10-10 광주과학기술원 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
GB201106433D0 (en) 2011-04-15 2011-06-01 Reckitt & Colman Overseas Composition and method
EP2522689A1 (en) 2011-05-13 2012-11-14 Universität Bayreuth Non-viral transfection systems
WO2012158610A1 (en) 2011-05-13 2012-11-22 William Marsh Rice University Temperature-assisted migration of amphiphilic nanoparticles through liquid interfaces
EP2523002A1 (en) 2011-05-13 2012-11-14 Universität Bayreuth Utilization of magnetic nanoparticles as intracellular pull-down system
CN102250278B (zh) 2011-05-26 2013-04-10 华东理工大学 用于水溶性固定化纤维素酶的pH敏感再生型聚合物及其制备方法与应用
KR101337672B1 (ko) 2011-06-02 2013-12-31 경희대학교 산학협력단 베타―d―글루코스 펜타키스(3,4―디하이드록시―5―((3,4,5―트리하이드록시벤조일)옥시)벤조에이트)를 유효성분으로 포함하는 신장결석 예방 및 치료용 조성물
KR101280720B1 (ko) 2011-06-03 2013-07-26 경희대학교 산학협력단 1,2,3,4,6―펜타―오―갈로일―베타―디―글루코오스및 이마티니브를 유효성분으로 포함하는 만성 골수성 백혈병 치료용 조성물
US20140235790A1 (en) 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
JP2013029832A (ja) 2011-06-22 2013-02-07 Dainippon Printing Co Ltd カラーフィルタ用硬化性樹脂組成物、カラーフィルタ、液晶表示装置及び有機発光表示装置、並びにカラーフィルタ用顔料分散液
GB201111216D0 (en) 2011-07-01 2011-08-17 Reckitt & Colman Overseas Composition and method
WO2013003887A1 (en) 2011-07-04 2013-01-10 Commonwealth Scientific And Industrial Research Organisation Nucleic acid complex
KR101302315B1 (ko) 2011-07-19 2013-08-30 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
KR101282847B1 (ko) 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
JP5807438B2 (ja) 2011-08-12 2015-11-10 富士ゼロックス株式会社 二成分現像剤用キャリア、二成分現像剤、画像形成方法、及び、画像形成装置
CN102949342A (zh) 2011-08-24 2013-03-06 天津金耀集团有限公司 一种含有睾酮的透皮吸收药物组合物
EP2749577B1 (en) 2011-08-25 2018-09-19 Kyoto University Living radical polymerization method
KR101454066B1 (ko) 2011-09-08 2014-10-24 경희대학교 산학협력단 아스퍼질러스 나이저의 배양액에서 분리한 인삼 사포닌 전환활성을 갖는 효소, 이의 제조방법, 이를 이용한 효소처리 인삼 추출물, 효소처리 인삼 추출물의 제조방법 및 효소처리 인삼 추출물을 포함하는 피부미용 개선용 조성물
KR101384873B1 (ko) 2011-09-20 2014-04-16 경희대학교 산학협력단 인삼(Panax ginseng) 및 산사(Crataegis fructus) 추출물을 포함하는 피부미용 개선용 조성물
US20130129869A1 (en) 2011-11-23 2013-05-23 Hooman Hafezi Compositions comprising a shelf-life stability component
JP5735405B2 (ja) 2011-11-30 2015-06-17 株式会社Dnpファインケミカル 着色樹脂組成物、カラーフィルタ、及び液晶表示装置
JP5781706B2 (ja) 2011-12-29 2015-09-24 アッヴィ・アイルランド・アンリミテッド・カンパニー Hcv阻害剤を含む固体組成物
WO2013135853A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical packaging product for the veterinary medical sector
MX2014001965A (es) * 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
JP2013237821A (ja) 2012-05-17 2013-11-28 Teijin Ltd (メタ)アクリル酸共重合体
CA2874455C (en) 2012-05-22 2016-10-11 Kuhnil Pharm. Co., Ltd. Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
CA2872446A1 (en) 2012-05-22 2013-11-28 Dsm Ip Assets B.V. Composition and process for making a porous inorganic oxide coating
JP2014024537A (ja) 2012-06-19 2014-02-06 3M Innovative Properties Co ナンバープレート用シート、ナンバープレート用積層体、ナンバープレートおよびナンバープレート用装飾部材
TWI506064B (zh) 2012-07-23 2015-11-01 Innocom Tech Shenzhen Co Ltd 量子點高分子複合膜及其製造方法
KR101633957B1 (ko) 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
BR112015006056A2 (pt) 2012-09-18 2017-07-04 Abbvie Inc métodos para tratar hcv
EP2897609A1 (en) 2012-09-18 2015-07-29 AbbVie Inc. Methods for treating hepatitis c
SMT201900683T1 (it) 2012-09-18 2020-01-14 Abbvie Inc Metodi per il trattamento di epatite c
US10172956B2 (en) 2012-10-26 2019-01-08 Vanderbilt University Polymeric nanoparticles
US8758860B1 (en) 2012-11-07 2014-06-24 Bayer Materialscience Llc Process for incorporating an ion-conducting polymer into a polymeric article to achieve anti-static behavior
US9585826B2 (en) 2012-11-07 2017-03-07 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of active chemistry
US9447220B2 (en) 2012-11-19 2016-09-20 Rohm And Haas Electronic Materials Llc Self-assembled structures, method of manufacture thereof and articles comprising the same
KR101312286B1 (ko) 2012-11-26 2013-09-27 (주)비씨월드제약 즉시방출 및 조절방출 특성을 갖고 d-트레오-메틸페니데이트를 포함하는 약학 조성물
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
TW201434936A (zh) 2013-01-11 2014-09-16 Nippon Soda Co 無機粒子用分散劑、含有該分散劑之組成物、硬化性組成物、硬化物及薄膜
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
KR101431957B1 (ko) 2013-01-25 2014-08-19 경희대학교 산학협력단 피세틴 및 설퍼레틴을 유효성분으로 포함하는 염증성 질환 개선용 조성물
CN103113509B (zh) 2013-01-30 2016-05-04 华东理工大学 以l-甲状腺素为亲和配基的再生型亲和沉淀剂及制备方法和应用以及相关再生型聚合物
KR20140105941A (ko) 2013-02-25 2014-09-03 건양대학교산학협력단 어류 양식용 부상성(浮上性) 사료 및 그 제조 방법
JP6309980B2 (ja) 2013-02-25 2018-04-11 ユニバーシティ オブ ロチェスター 抗バイオフィルム剤を制御放出するためのナノ粒子及びその使用方法
CN105142616B (zh) 2013-03-01 2018-02-13 Bpsi控股有限责任公司 含有硅酸钙的延迟释放薄膜包衣及其包被的底物
WO2014159340A1 (en) 2013-03-13 2014-10-02 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
HK1216862A1 (zh) 2013-03-26 2016-12-09 橘生药品工业株式会社 西洛多辛苦味被掩蔽的口服给药制剂
KR101502588B1 (ko) 2013-05-01 2015-03-16 한국유나이티드제약 주식회사 클로피도그렐 및 아스피린의 복합제제
CN103255174B (zh) 2013-05-02 2015-10-28 天津大学 以聚乙二醇接枝的透明质酸为外层的三元复合物及三元复合物的液体与应用
CN103319668B (zh) 2013-06-25 2015-11-11 常州大学 一种甲基丙烯酸丁酯-甲基丙烯酸二甲氨基乙酯嵌段共聚物的制备方法
KR101458468B1 (ko) 2013-06-27 2014-11-10 한국화학연구원 신규한 공중합체를 함유하는 제조가 용이한 리튬 이차전지용 겔 고분자 전해질
CN103536972B (zh) 2013-07-05 2016-01-13 北京大学 磁共振成像可检测的液体栓塞组合物及其制备和应用
CN103333283B (zh) 2013-07-15 2015-09-09 华东理工大学 可形成偏碱性两水相体系的两种pH响应再生型聚合物及其制备方法与应用
US20150045353A1 (en) 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
US20140161893A1 (en) 2013-08-16 2014-06-12 University Of Washington Through Its Center For Commercialization Polymer blend particles for intracellular delivery of agents
EP2842548A1 (en) 2013-08-29 2015-03-04 Universite De Liege Polymeric synthetic antidote
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
RU2646501C2 (ru) 2013-09-11 2018-03-05 3М Инновейтив Пропертиз Компани Композиции для полости рта
US9970040B2 (en) * 2013-09-26 2018-05-15 Massachusetts Institute Of Technology Engineering DNA assembly in vivo and methods of making and using the reverse transcriptase technology
EP3052150B1 (en) 2013-09-30 2021-02-17 Lucite International Speciality Polymers and Resins Limited A hardenable multi-part acrylic composition
GB201317299D0 (en) 2013-09-30 2013-11-13 Lucite Int Uk Ltd A hardenable multi-part acrylic composition
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20160243221A1 (en) 2013-10-18 2016-08-25 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
US9119780B2 (en) 2013-10-30 2015-09-01 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of proactive chemistry
EP3068378A4 (en) 2013-11-12 2017-05-03 University Of Washington Through Its Center For Commercialization Random copolymer therapeutic agent carriers and assemblies thereof
CA2929991A1 (en) * 2013-11-28 2015-06-04 Commonwealth Scientific And Industrial Research Organisation Mikto-arm branched polymers
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
CN106061292B (zh) 2013-12-16 2020-01-21 麻省理工学院 强化的微量营养素盐调配物
EP3208651A1 (en) 2013-12-23 2017-08-23 3M Innovative Properties Company Optical article
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN103755870B (zh) 2014-01-06 2016-10-26 苏州大学 一种含多巴胺无规共聚物及其精细制备方法和应用
US20170002060A1 (en) 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
US20150232729A1 (en) 2014-02-20 2015-08-20 Georgia Southern Research and Service Foundation Antifogging compositions and methods of making the same
CA2941612A1 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
KR101663791B1 (ko) 2014-03-07 2016-10-10 한국과학기술원 생체분자를 타겟팅하는 하이브리드 나노구조체
US9750814B2 (en) 2014-03-12 2017-09-05 University Of Washington Polypeptides to inhibit epstein barr viral protein BHRF1 and B cell lymphoma family proteins
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN103976972B (zh) 2014-05-26 2017-09-12 中国药科大学 酒石酸唑吡坦口服脉冲控释给药系统及其制备方法
IL291842A (en) 2014-06-10 2022-06-01 Afyx Therapeutics As Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
RU2706791C2 (ru) 2014-07-03 2019-11-21 Пфайзер Инк. Направленно доставляемые терапевтические наночастицы и способы их получения и использования
GB201412955D0 (en) 2014-07-22 2014-09-03 Aqdot Ltd Supramolecular capsules
WO2016025747A1 (en) * 2014-08-13 2016-02-18 Stayton Patrick S Nonlinear copolymers as intracellular delivery vehicles and related methods
JP6265093B2 (ja) 2014-09-22 2018-01-24 Jsr株式会社 着色組成物、着色硬化膜、並びに表示素子及び固体撮像素子
CN107075274B (zh) 2014-10-21 2019-12-13 帝斯曼知识产权资产管理有限公司 聚合物、方法和用途
WO2016065306A1 (en) 2014-10-23 2016-04-28 The Brigham And Women's Hospital, Inc. Amphiphile-polymer particles
FR3027802B1 (fr) 2014-10-31 2018-03-02 Ethypharm Granules de principe actif a double masquage de gout, leur procede de preparation et comprimes orodispersibles les contenant
KR20170083071A (ko) 2014-11-11 2017-07-17 시오노기 앤드 컴파니, 리미티드 광에 대해서 불안정한 약물을 함유하는 다층 정제
RU2582704C1 (ru) 2014-12-15 2016-04-27 Общество с ограниченной ответственностью "СКИФ Спешиал Кемикалз" Состав для поверхностной проклейки бумаги и картона
CN104479064B (zh) 2014-12-18 2016-08-24 中国海洋石油总公司 一种聚驱采出液处理用反相破乳剂及其制备方法
JP2016126154A (ja) 2014-12-26 2016-07-11 花王株式会社 カラーフィルター用顔料分散体
EP3247328B1 (en) 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
WO2016134121A1 (en) 2015-02-20 2016-08-25 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
CN104772051A (zh) 2015-03-25 2015-07-15 浙江工业大学 一种共聚物亲水改性超滤膜及其制备方法与应用
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
CN104784155B (zh) 2015-05-15 2018-02-23 中国药科大学 一种盐酸普拉克索组合微丸胶囊及其制备方法
KR101764785B1 (ko) 2015-05-29 2017-08-07 한국유나이티드제약 주식회사 약제학적 복합제제
CN104971073B (zh) 2015-05-29 2018-01-12 西南药业股份有限公司 法莫替丁钙镁咀嚼片的制备方法及其产品
EA201890068A1 (ru) 2015-06-17 2018-09-28 Байоджен Ма Инк. Частицы диметилфумарата и фармацевтические композиции на их основе
CN104922078B (zh) 2015-06-23 2018-10-23 上海市计划生育科学研究所 非诺贝特迟释微丸、制备方法及应用
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017009865A1 (en) 2015-07-10 2017-01-19 Sun Pharma Advanced Research Company Ltd. Multiple pill abuse-resistant immediate release solid dosage form of hydrocodone
JP2017058405A (ja) 2015-09-14 2017-03-23 富士ゼロックス株式会社 静電荷像現像剤、現像剤カートリッジ、プロセスカートリッジ、画像形成装置、及び、画像形成方法
US20180237800A1 (en) 2015-09-21 2018-08-23 The Regents Of The University Of California Compositions and methods for target nucleic acid modification
BR112018006206A2 (pt) 2015-09-29 2018-10-09 Achillion Pharmaceuticals Inc composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
JP6954648B2 (ja) 2015-10-19 2021-10-27 シージー オンコロジー, インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
KR102435996B1 (ko) 2015-11-19 2022-08-25 에이에프와이엑스 테라퓨틱스 에스에이 전기수력학적으로 수득된 섬유를 포함하는 약학적 조성물, 적용 부위에서 향상된 체류 시간을 갖는 조성물
US20170296484A1 (en) 2015-11-23 2017-10-19 Grace Therapeutics Llc Topical Film-Forming Spray
US10874991B2 (en) 2015-11-27 2020-12-29 Queen's University At Kingston Functional filters for hydrophobic liquid/hydrophilic liquid separations
CN105504923B (zh) 2015-12-07 2017-11-21 常州大学 一种快干型无溶剂涂料及其制备方法
KR102408645B1 (ko) 2015-12-24 2022-06-14 (주)휴온스 안정성이 증가된 에스오메프라졸 함유 이중코팅정 조성물 및 이의 제조방법
CA3007577A1 (en) 2015-12-28 2017-07-06 Nippon Shinyaku Co., Ltd. Compression-molded preparation
JP7156945B2 (ja) 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
FR3048700B1 (fr) 2016-03-08 2019-11-08 Arkema France Films poreux obtenus a partir de latex de polymeres
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
ES2935158T3 (es) 2016-03-17 2023-03-02 Sun Pharmaceutical Ind Ltd Composición farmacéutica de nilotinib
KR102304478B1 (ko) 2016-04-04 2021-09-24 주식회사 바오밥에이바이오 Ras를 분해하는 이종원자고리화합물 및 이의 용도
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
CN105833272B (zh) 2016-04-20 2020-08-21 国家纳米科学中心 一种多功能纳米药物组合物及其制备方法与应用
CN105833287B (zh) 2016-04-20 2020-07-10 国家纳米科学中心 一种缓释纳米药物载体及其制备方法与应用
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2017189963A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
CN105949365B (zh) 2016-05-30 2018-10-19 山东鲁岳化工有限公司 一种珠状超高粘度水溶性阳离子聚合物及其制备方法
WO2017210666A2 (en) 2016-06-03 2017-12-07 Stemgenics, Inc. Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
CN106117580A (zh) 2016-06-23 2016-11-16 广州新克力生物科技有限公司 一种用于滤除白细胞的滤膜改性剂及其改性方法
US9910353B2 (en) 2016-07-29 2018-03-06 Dow Global Technologies Llc Method of negative tone development using a copolymer multilayer electrolyte and articles made therefrom
US9910355B2 (en) 2016-07-29 2018-03-06 Rohm And Haas Electronic Materials Llc Method of negative tone development using a copolymer multilayer electrolyte and articles made therefrom
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
JP6638706B2 (ja) 2016-08-03 2020-01-29 東ソー株式会社 ブロック共重合体およびそれを用いた表面処理剤
CN106236785B (zh) 2016-08-28 2019-08-27 福州海王金象中药制药有限公司 多糖蛋白片制备工艺
KR101847604B1 (ko) 2016-09-09 2018-04-11 주식회사 웨피 자외선 차단 성능이 우수한 수성 열반사 보온 단열도료 및 그 제조방법
CN106478904B (zh) 2016-09-26 2018-10-26 同济大学 一种具有温度和pH敏感性的多嵌段共聚物材料的制备方法
KR20190065344A (ko) 2016-10-03 2019-06-11 회가내스 아베 (피유비엘) 백색 철 식품 첨가제
KR102072546B1 (ko) 2016-10-14 2020-02-04 주식회사 삼양바이오팜 레날리도마이드의 경구용 정제 조성물
WO2018079573A1 (ja) 2016-10-26 2018-05-03 味の素株式会社 消化管における吸収低下の改善用組成物、および消化管における吸収の促進用組成物
KR101827744B1 (ko) 2016-10-31 2018-02-09 부광약품 주식회사 톨리미돈의 대량 제조 방법
US20200086616A1 (en) 2016-12-16 2020-03-19 Basf Se Multi-layered film , method for the production and use thereof
WO2018112555A1 (en) 2016-12-22 2018-06-28 Commonwealth Scientific And Industrial Research Organisation Aqueous polymer composition
JP2020502226A (ja) * 2016-12-23 2020-01-23 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 薬物の標的送達のための生体適合性の親水性ポリマーコンジュゲート
KR101850629B1 (ko) 2016-12-28 2018-04-20 연세대학교 원주산학협력단 항균제가 담지된 금속이중층수산화물 나노구조체를 함유하는 신선편이 농산물의 선도 유지용 조성물
BR112019015107A2 (pt) 2017-01-23 2020-03-10 Dong Wha Pharm. Co., Ltd. Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2018139626A1 (ja) 2017-01-30 2018-08-02 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤
CN106811998B (zh) 2017-02-15 2019-09-24 山东聚发生物科技有限公司 一种交联型无醛固色剂乳液及其制备方法
WO2018155555A1 (ja) 2017-02-27 2018-08-30 Jsr株式会社 基材表面の選択的修飾方法
KR20180099263A (ko) 2017-02-28 2018-09-05 경남대학교 산학협력단 피세틴을 포함하는 피부건강용 조성물
JP2018154752A (ja) 2017-03-17 2018-10-04 東ソー株式会社 共重合体およびその製造方法
JP7127330B2 (ja) 2017-04-12 2022-08-30 東ソー株式会社 ブロック共重合体およびそれを用いた表面処理剤
KR102542711B1 (ko) 2017-04-13 2023-06-12 오지 홀딩스 가부시키가이샤 가식 성형용 점착 시트
WO2018192910A2 (en) 2017-04-18 2018-10-25 Dsm Ip Assets B.V. Process for making an anti-soiling coating composition and a coating made therefrom
EP3615147B1 (de) 2017-04-28 2024-09-11 Symrise AG Schafgarbe frischpflanzenpresssaft konzentrat, herstellung und verwendung
KR102082775B1 (ko) 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
WO2018213361A1 (en) 2017-05-15 2018-11-22 Vanderbilt University LONG-CIRCULATING ZWITTERIONIC POLYPLEXES FOR siRNA DELIVERY
JP2018203987A (ja) 2017-05-30 2018-12-27 東ソー株式会社 表面処理剤のコート方法
KR20200014353A (ko) 2017-06-02 2020-02-10 사우디 아라비안 오일 컴퍼니 코팅된 실리카 입자
CN107173546A (zh) 2017-06-12 2017-09-19 揭阳市润达肠衣有限公司 一种含大蒜精油的掩味控释颗粒及其制备方法和应用
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
FR3068704B1 (fr) 2017-07-06 2021-02-19 Centre Nat Rech Scient Materiau solide organique antibacterien
WO2019027767A1 (en) 2017-07-31 2019-02-07 Illumina Inc. SEQUENCING SYSTEM COMPRISING AGGREGATION OF MULTIPLEXED BIOLOGICAL SAMPLES
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
EP3668484B1 (en) 2017-08-17 2022-07-13 F. Hoffmann-La Roche AG Novel pharmaceutical compositions for basic or neutral, low molecular weight compounds
US11013695B2 (en) 2017-08-28 2021-05-25 Wisconsin Alumni Research Foundation Nanocapsule delivery system for ribonucleoproteins
KR102394794B1 (ko) 2017-09-01 2022-05-04 현대자동차주식회사 탄소섬유 강화 고분자 복합재료 및 이의 제조방법
US11125748B2 (en) 2017-09-01 2021-09-21 University Of British Columbia Method for organizing individual molecules on a patterned substrate and structures assembled thereby
WO2019048962A1 (en) 2017-09-08 2019-03-14 3M Innovative Properties Company AQUEOUS FLUORIDE TREATMENT COMPOSITIONS FOR ORAL CARE, AND METHODS
MA50189A (fr) 2017-09-22 2021-05-19 Dispersol Technologies Llc Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
CN107596368B (zh) 2017-10-11 2020-02-14 华南师范大学 一种细菌靶向纳米粒子的制备及其抑杀细菌的应用
MX2020004491A (es) 2017-10-30 2020-08-13 Kaken Pharma Co Ltd Preparacion externa para tratar tinea unguium.
KR102184117B1 (ko) 2017-10-31 2020-11-30 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
EP3705118B1 (en) 2017-10-31 2024-02-14 Samyang Holdings Corporation Oral solid dosage form composition having improved disintegration and preparation method therefor
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
US20210163933A1 (en) 2017-12-11 2021-06-03 University Of Massachusetts Arc protein extracellular vesicle nucleic acid delivery platform
WO2019126627A1 (en) * 2017-12-22 2019-06-27 Rensselaer Polytechnic Institute Dna origami nanoparticle delivery of programmed chromosome breakage machinery
US10920061B2 (en) 2017-12-29 2021-02-16 Kyungpook National University Industry-Academic Cooperation Foundation Self-healing acrylic copolymer, crosslinked copolymer prepared from the acrylic copolymer and method for low-temperature self-healing of the crosslinked copolymer
US10201503B1 (en) 2018-01-09 2019-02-12 Triastek, Inc. Precision pharmaceutical 3D printing device
JP6959154B2 (ja) 2018-01-23 2021-11-02 大阪有機化学工業株式会社 化粧料組成物
US11253484B2 (en) 2018-01-30 2022-02-22 Nitto Denko Corporation Transdermal absorption preparation
WO2019152957A1 (en) * 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
EP3759225A1 (en) * 2018-03-02 2021-01-06 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
KR20190111448A (ko) 2018-03-23 2019-10-02 주식회사 제이와이에스앤텍 부착용 방담필름
JP7581052B2 (ja) 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物
GB201807853D0 (en) 2018-05-15 2018-06-27 Univ College Cardiff Consultants Ltd Polymers
US11702653B2 (en) 2018-05-21 2023-07-18 Battelle Memorial Institute Control compositions and methods for sequencing
KR101923028B1 (ko) 2018-05-28 2018-11-29 (주)무량기술 용융형 도로 표시용 조성물 및 이의 시공 방법
BR112020024269A2 (pt) 2018-05-31 2021-02-23 Hua Medicine (Shanghai) Ltd. combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos
US11344506B2 (en) 2018-07-11 2022-05-31 Cure Pharmaceutical Holding Corp. Rapidly disintegrating oral dissolvable film
KR102120720B1 (ko) 2018-07-16 2020-06-10 연성정밀화학(주) 날푸라핀 함유 구강붕해정
KR101943270B1 (ko) 2018-07-17 2019-01-28 코오롱제약주식회사 맛차폐된 시나칼셋 구강붕해정 및 그 제조방법
KR20200009744A (ko) 2018-07-20 2020-01-30 크리스탈지노믹스(주) Fab I 저해제를 포함하는 경구투여용 약제학적 조성물 및 그 제조방법
WO2020023612A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CN112912420A (zh) 2018-08-16 2021-06-04 巴斯夫欧洲公司 聚合物组合物
JP2021533177A (ja) 2018-08-23 2021-12-02 チョン クン ダン ファーマシューティカル コーポレイション エソメプラゾール及び炭酸水素ナトリウムを含む、優れた溶解特性を備えた薬学的製剤
US20200069696A1 (en) 2018-08-30 2020-03-05 Yunxiang Liu Ophthalmic injectable formulation preparing and oculopathy treating and preventing
US20210317479A1 (en) * 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
KR102300335B1 (ko) 2018-10-19 2021-09-10 주식회사 삼양홀딩스 아프레피탄트의 경구용 조성물
CN112955130A (zh) 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
BR112021007656A2 (pt) 2018-10-30 2021-07-27 Basf Se processo para produzir micropartículas carregadas com pelo menos um ativo orgânico de baixo peso molecular, composição de micropartículas preenchidas com pelo menos um ativo, produto, e, uso da composição.
US12508233B2 (en) 2018-10-30 2025-12-30 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
EP3873440A4 (en) 2018-11-01 2022-08-17 Molecular Infusions, LLC POLYMER-BASED ORAL CANNABINOID AND/OR TERPEN FORMULATIONS
JP7262206B2 (ja) 2018-11-07 2023-04-21 東ソー株式会社 溶出物試験方法
MX2021005997A (es) 2018-11-21 2021-08-11 Vectores virales recombinantes y acidos nucleicos para producirlos.
WO2020123661A1 (en) 2018-12-11 2020-06-18 Farokhzad Omid C Methods for treating cancer
KR20200090359A (ko) 2019-01-21 2020-07-29 크리스탈지노믹스(주) Fab I 저해제를 포함하는 주사제용 조성물 및 그 제조방법
WO2020154595A1 (en) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
CN121081491A (zh) 2019-03-04 2025-12-09 旗舰创业创新第六有限责任公司 环状多核糖核苷酸及其药物组合物
KR102107332B1 (ko) 2019-03-20 2020-05-07 (주)제이비바이오텍 CRISPR/Cas9 기반 Bacillus subtillis 유전체 편집 메커니즘을 이용한 콜레라 백신
US20200308331A1 (en) 2019-03-28 2020-10-01 Penn Color, Inc. Water compatible cationic graft copolymers and ink compositions comprising same
KR102349029B1 (ko) 2019-04-18 2022-01-10 한양대학교 에리카산학협력단 자극 반응성을 가진 양친성 노보넨 기반 블럭 공중합체, 이의 고분자 브러쉬, 이의 초분자 자가조립 나노구조체, 이의 제조 방법 및 이의 응용
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
JP7568380B2 (ja) 2019-05-28 2024-10-16 トイメディカル株式会社 ナトリウム排出粒子
US20220233459A1 (en) 2019-06-05 2022-07-28 Guide Therapeutics, Inc. Analysis of materials for tissue delivery
KR102157964B1 (ko) 2019-06-13 2020-09-22 (주)제이비바이오텍 CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 돼지의 아프리카 돼지열병 백신
WO2021007382A1 (en) 2019-07-09 2021-01-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
KR102207353B1 (ko) 2019-08-28 2021-01-27 (주)제이비바이오텍 CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 돼지의 괴사성장염 백신
KR102207354B1 (ko) 2019-09-02 2021-01-27 (주)제이비바이오텍 CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 닭의 괴사성장염 백신
US11564884B2 (en) 2019-09-09 2023-01-31 Regents Of The University Of Minnesota Cationic block polymer micelles for delivery of biological agents
EP4045655A4 (en) 2019-10-16 2024-02-28 King Abdullah University Of Science And Technology METHOD FOR MODULATING HUMAN L1 RETRO TRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN
KR102212504B1 (ko) 2019-10-28 2021-02-08 주식회사 제이비바이오텍 농업회사법인 CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 개의 켄넬코프 백신
KR102212505B1 (ko) 2019-10-28 2021-02-05 주식회사 제이비바이오텍 농업회사법인 CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 벌의 낭충봉아부패 백신
KR102212503B1 (ko) 2019-10-28 2021-02-05 주식회사 제이비바이오텍 농업회사법인 CRISPR/Cas9 기반 Bacillus subtilis 유전체 편집 메커니즘을 이용한 넙치의 스쿠티카증 백신
KR102842351B1 (ko) 2019-11-05 2025-08-04 아주대학교산학협력단 레바미피드 또는 이의 약학적으로 허용가능한 염을 포함하는 경구투여용 서방성 약학 조성물
CN115175668A (zh) 2019-12-20 2022-10-11 三养控股公司 具有改善的奥拉帕尼的溶解度和生物利用率的组合物
WO2021145655A1 (ko) 2020-01-13 2021-07-22 압타바이오 주식회사 신규한 피라졸 유도체
JP2023511282A (ja) 2020-01-14 2023-03-17 シンロジック オペレーティング カンパニー インコーポレイテッド シュウ酸塩が有害となる障害を治療するための遺伝子改変細菌
KR102366598B1 (ko) 2020-03-20 2022-02-24 광주과학기술원 양쪽 이온성 관능기를 가지는 랜덤 공중합체를 포함하는 공기 필터용 나노섬유 및 그 제조방법
KR20210119906A (ko) 2020-03-25 2021-10-06 주식회사 삼양홀딩스 포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법
KR102672103B1 (ko) 2020-04-01 2024-06-04 연세대학교 산학협력단 노로바이러스성 질환의 치료용 조성물
DE102020002360A1 (de) 2020-04-18 2021-10-21 Friedrich-Schiller-Universität Jena Nanopartikel enthaltend Komplexe aus Nukleinsäuren und kationischen Copolymeren, Verfahren zu deren Herstellung und deren Verwendung zum Gentransfer in Zellen
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
EP3960203A1 (en) 2020-08-25 2022-03-02 Université de Liège Complexes for the delivery of proteinaceous agents
JP7533087B2 (ja) 2020-09-30 2024-08-14 日油株式会社 共重合体、共重合体の製造方法、細胞凍結保存材及び細胞凍結保存液
CA3196560A1 (en) 2020-10-27 2022-05-05 Mitsubishi Pencil Company, Limited Marker composition for skin
JP2022076360A (ja) 2020-11-09 2022-05-19 日本電信電話株式会社 形状記憶性高分子積層膜およびその製造方法
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
EP4015634A1 (en) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
WO2022139687A1 (en) 2020-12-23 2022-06-30 Croda Singapore Pte Limited Soot dispersant comprising block copolymer and lubricant composition containing the same
JP2022117407A (ja) 2021-01-29 2022-08-10 花王株式会社 外用剤組成物
IL305336B2 (en) 2021-03-11 2025-09-01 Nautilus Subsidiary Inc Systems and methods for preserving biomolecules
WO2022197654A1 (en) 2021-03-15 2022-09-22 E Ink Corporation Switchable light modulator having regions of varying opacity
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
EP4340847A4 (en) 2021-05-21 2024-07-17 ILKO Ilaç Sanayi ve Ticaret A.S. MESALAZIN-BASED ENTERIC TABLET FORMULATION COMPOSITION
CN117677708A (zh) 2021-06-09 2024-03-08 麻省理工学院 序列控制聚合物存储
WO2022266119A1 (en) 2021-06-16 2022-12-22 Edwards Lifesciences Corporation Multifunctional sealing member for improved endothelialization and paravalvular leakage
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
WO2023107574A2 (en) 2021-12-07 2023-06-15 The Brigham And Women’S Hospital, Inc. Lipid-based compositions and methods thereof
PL245677B1 (pl) 2022-02-23 2024-09-16 Podkarpackie Centrum Innowacji Spolka Z Ograniczona Odpowiedzialnoscia Polimery gwiaździste, sposób otrzymywania polimerów gwiaździstych oraz ich zastosowanie
CN118660707A (zh) 2022-04-08 2024-09-17 北京睿创康泰医药研究院有限公司 超分子自组装体系
CA3258934A1 (en) 2022-06-09 2023-12-14 Battelle Memorial Institute NON-VIRAL ADMINISTRATION OF SMALL MOLECULE THERAPEUTIC AGENTS
AU2023285047A1 (en) 2022-06-09 2024-12-12 Battelle Memorial Institute Non-viral delivery compositions and screening methods
WO2024036356A1 (en) * 2022-08-15 2024-02-22 Newsouth Innovations Pty Limited Additive manufacturing method
CN115714187A (zh) 2022-10-12 2023-02-24 池州学院 一种中间催化层改性的双极膜及其制备方法

Also Published As

Publication number Publication date
US20240415865A1 (en) 2024-12-19
EP4255495A1 (en) 2023-10-11
US20220175812A1 (en) 2022-06-09
CN116887866A (zh) 2023-10-13
US20260014186A1 (en) 2026-01-15
IL303390A (en) 2023-08-01
US20240189338A1 (en) 2024-06-13
US12433910B2 (en) 2025-10-07
AU2021391823A9 (en) 2024-10-10
WO2022120194A1 (en) 2022-06-09
US12109223B2 (en) 2024-10-08
JP2023553010A (ja) 2023-12-20
CA3203975A1 (en) 2022-06-09
EP4255495A4 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
US12433910B2 (en) Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
Yang et al. Self-assembled double-bundle DNA tetrahedron for efficient antisense delivery
Cho et al. Synthesis of biocompatible PEG-based star polymers with cationic and degradable core for siRNA delivery
Huh et al. pH-sensitive polymers for drug delivery
Jain et al. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery
Yang et al. Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan/siRNA nanoparticles in vitro and in vivo
Sunshine et al. Poly (β-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo
Taranejoo et al. Bioreducible PEI-functionalized glycol chitosan: A novel gene vector with reduced cytotoxicity and improved transfection efficiency
US8936907B2 (en) Neural transfection reagents
Sunasee et al. Biodegradable and nontoxic nanogels as nonviral gene delivery systems
Haladjova et al. Polymeric nanoparticle engineering: from temperature-responsive polymer mesoglobules to gene delivery systems
Peterson et al. Controlling self‐assembly of DNA‐polymer conjugates for applications in imaging and drug delivery
WO2022216977A1 (en) Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
Street et al. Length-controlled nanofiber micelleplexes as efficient nucleic acid delivery vehicles
Fay et al. Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles
Helal et al. Non-viral gene delivery systems: hurdles for bench-to-bedside transformation
Xiong et al. Engineered Aptamer‐Organic Amphiphile Self‐Assemblies for Biomedical Applications: Progress and Challenges
CN115715186A (zh) 含核酸与阳离子共聚物的复合物的纳米粒子及其制备方法、用于基因转移至细胞中的用途
Kly et al. Hierarchical self-assembly route to “polyplex-in-hydrophobic-core” micelles for gene delivery
Thomas et al. Dextran–glycidyltrimethylammonium chloride conjugate/DNA nanoplex: A potential non-viral and haemocompatible gene delivery system
Yang et al. Synthetic conjugated Oligoelectrolytes are effective siRNA transfection carriers: relevance to pancreatic cancer gene therapy
Chen et al. αvβ3 Receptor-targeted acid-responsive controlled-release endosome escape doxorubicin-loaded liposomes for A549/ADR treatment
Lawson et al. The spatial distribution of lipophilic cations in gradient copolymers regulates polymer–pDNA complexation, polyplex aggregation, and intracellular pDNA delivery
Bristow et al. Aptamer-targeted dendrimersomes assembled from azido-modified Janus dendrimers “clicked” to DNA
JP2017515839A (ja) 合成脳浸透遺伝子ベクターの操作

Legal Events

Date Code Title Description
SREP Specification republished